Literature DB >> 31162300

Müller's Muscle-conjunctival Resection Combined With Tarsectomy for Treatment of Congenital Ptosis.

Inbal Gazit1,2, Juliana Gildener-Leapman1,2, Lior Or1,2, Cat N Burkat3, Eran Pras1,2, Morris E Hartstein1,2.   

Abstract

PURPOSE: To evaluate the efficacy of Müller's muscle-conjunctival resection combined with tarsectomy for the treatment of congenital ptosis.
METHODS: A retrospective, noncomparative case series was performed on 38 eyes of 36 patients who underwent Müller's muscle-conjunctival resection combined with tarsectomy for the treatment of congenital ptosis. Age range was 2-25 years (mean: 7.86 years). Follow-up measurements taken up to 4 years after procedure were compared with baseline values.
RESULTS: Thirty-six patients presenting with congenital ptosis underwent Müller's muscle-conjunctival resection combined with tarsectomy. All patients had fair-to-good levator function of 5-10 mm. A mean improvement in the margin reflex distance-1 of 2.79 mm (p value < 0.0001) was noted. All cases except one achieved excellent lid height and postoperative symmetry of the eyelids.
CONCLUSIONS: Müller's muscle-conjunctival resection combined with tarsectomy is a safe and effective procedure in the treatment of congenital ptosis in patients with moderate-to-good levator function. The surgery is rapid with quick recovery time. No complications were noted.The authors describe a retrospective case analysis of patients who underwent Müller's muscle-conjunctival resection combined with tarsectomy, for the treatment of congenital ptosis with moderate-to-good levator function, demonstrates excellent results.

Entities:  

Mesh:

Year:  2019        PMID: 31162300     DOI: 10.1097/IOP.0000000000001410

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  1 in total

1.  Efficacy and predictability of Muller's muscle-conjunctival resection with different tarsectomy lengths for unilateral blepharoptosis treatment.

Authors:  So-Hung Yeh; Shu-Lang Liao; Yi-Hsuan Wei
Journal:  BMC Ophthalmol       Date:  2021-02-12       Impact factor: 2.209

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.